Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Miricorilant for Olanzapine-Induced Weight Gain
NCT03877562Phase 1Completed
- Sponsor
- Corcept Therapeutics
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in antipsychotic-induced weight gain (AIWG) comparing Olanzapine + Miricorilant with Olanzapine + Placebo (2 arms). Primary endpoint: Mean Change from Baseline in Body Weight at Day 15. Started Apr 2019; status: completed.
02
Drugs
miricorilant
03
Conditions
antipsychotic-induced weight gain (AIWG)
Beyond the preview
Go deeper on NCT03877562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03877562.